Latest Conference Articles

March 4th 2019, 12:26am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

New agents in chronic lymphocytic leukemia are significantly strengthening the armamentarium, particularly next-generation BTK and PI3K inhibitors, and although toxicities remain an issue, tolerability may be improving.

March 3rd 2019, 11:36pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

More options are available than ever before for treating older patients with acute myeloid leukemia and fresh hopes are resting on combinations of venetoclax plus hypomethylating agents.

March 3rd 2019, 9:14pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Sagar Lonial, MD, discusses some of the emerging agents for the treatment of patients with late relapse in multiple myeloma.

March 3rd 2019, 4:33am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Prognostic indices for mantle cell lymphoma are good for classifying patients but do little in the way of guiding treatment, and often the best course of action is to watch and wait.

March 3rd 2019, 12:17am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The day is approaching that chemotherapy may be unnecessary for the treatment of patients with chronic lymphocytic leukemia.

March 2nd 2019, 10:49pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

William G. Wierda, MD, PhD, discusses how CAR T cells could become more effective in the treatment of patients with chronic lymphocytic leukemia.

March 2nd 2019, 8:39pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Elias Jabbour, MD, discusses the treatment options for patients with acute lymphoblastic leukemia across these various subgroups.

March 2nd 2019, 7:16pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Saad Z. Usmani, MD, FACP, shares his advice for the management of early relapse in patients with multiple myeloma.

March 2nd 2019, 6:43pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Carla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.

March 2nd 2019, 3:46am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Real-world data on the use of chimeric antigen receptor T-cell therapy in large B-cell lymphoma bear out the pivotal results from ZUMA-1 and demonstrate not only that the treatment approach is here, but also that it’s time to address issues of efficacy, safety, cost, and moving this approach into earlier lines of therapy.

March 2nd 2019, 3:23am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jorge E. Cortes, MD, discusses the current treatment options for patients with acute myeloid leukemia, including the use of quizartinib in patients with FLT3 mutations, as well as data from the QuANTUM-R trial.

March 2nd 2019, 1:03am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.

March 1st 2019, 11:53pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.

March 1st 2019, 11:47pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

B-cell maturation antigen-specific chimeric antigen receptor T-cell therapy is delivering impressive results in multiple myeloma, demonstrating durable responses and acceptable toxicities.

February 28th 2019, 11:32pm

AACR Annual Meeting

Pre-existing cardiovascular disease was associated with an increased mortality risk during the first 6 months of abiraterone acetate treatment in patients with advanced prostate cancer.

February 28th 2019, 3:24am

AACR Annual Meeting

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.

February 28th 2019, 3:09am

AACR Annual Meeting

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

February 28th 2019, 3:07am

AACR Annual Meeting

Select patients with melanoma who consume a diet rich in fiber could see an improved response to treatment with immunotherapy.

February 25th 2019, 4:34am

Transplantation and Cellular Therapy Meetings

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

February 25th 2019, 2:53am

Transplantation and Cellular Therapy Meetings

Chimeric antigen receptor T cells targeting CD30 proved to be safe and active in relapsed/refractory Hodgkin lymphoma.